-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Genocea Biosciences (NASDAQ:GNCA) Receives New Coverage from Analysts at StockNews.com
Genocea Biosciences (NASDAQ:GNCA) Receives New Coverage from Analysts at StockNews.com
Investment analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Monday. The firm set a "sell" rating on the biotechnology company's stock.
A number of other research analysts have also weighed in on the company. HC Wainwright lowered Genocea Biosciences from a "buy" rating to a "neutral" rating in a report on Friday, April 29th. Stifel Nicolaus lowered Genocea Biosciences from a "buy" rating to a "hold" rating in a report on Friday, April 29th. Finally, Robert W. Baird cut their price objective on Genocea Biosciences from $8.00 to $3.00 in a report on Monday, April 11th.
Get Genocea Biosciences alerts:Genocea Biosciences Trading Down 6.7 %
Shares of NASDAQ:GNCA opened at $0.01 on Monday. The business's 50-day moving average is $0.03 and its 200 day moving average is $0.56. Genocea Biosciences has a 1 year low of $0.01 and a 1 year high of $2.20. The firm has a market capitalization of $657,820.80, a P/E ratio of -0.02 and a beta of 2.26. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.
Insider Buying and Selling
In related news, Director Ali Behbahani sold 4,445,093 shares of the firm's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total transaction of $355,607.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, major shareholder Paul Edward Walker sold 5,931,843 shares of the firm's stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $0.07, for a total transaction of $415,229.01. Following the sale, the insider now directly owns 4,445,093 shares of the company's stock, valued at $311,156.51. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ali Behbahani sold 4,445,093 shares of the firm's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total value of $355,607.44. The disclosure for this sale can be found here. Insiders have sold a total of 10,537,612 shares of company stock valued at $781,461 over the last ninety days. Company insiders own 1.61% of the company's stock.Institutional Trading of Genocea Biosciences
An institutional investor recently raised its position in Genocea Biosciences stock. Commonwealth Equity Services LLC boosted its holdings in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the quarter. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 59.25% of the company's stock.
Genocea Biosciences Company Profile
(Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Recommended Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Use These To Find Your Stock's Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter's Up For Third Week In A Row: What's Next For The Stock?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
Investment analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Monday. The firm set a "sell" rating on the biotechnology company's stock.
斯托克新闻网的投资分析师在周一发布的一份报告中假设了Genocea Biosciences(纳斯达克代码：GNCA-GET Rating)的股票。该公司对这家生物技术公司的股票设定了“卖出”评级。
A number of other research analysts have also weighed in on the company. HC Wainwright lowered Genocea Biosciences from a "buy" rating to a "neutral" rating in a report on Friday, April 29th. Stifel Nicolaus lowered Genocea Biosciences from a "buy" rating to a "hold" rating in a report on Friday, April 29th. Finally, Robert W. Baird cut their price objective on Genocea Biosciences from $8.00 to $3.00 in a report on Monday, April 11th.
其他一些研究分析师也加入了对该公司的看法。在4月29日星期五的一份报告中，HC Wainwright将Genocea Biosciences的评级从“买入”下调至“中性”。Stifel Nicolaus在4月29日星期五的一份报告中将Genocea Biosciences的评级从“买入”下调至“持有”。最后，罗伯特·W·贝尔德在4月11日星期一的一份报告中将他们对Genocea Biosciences的目标价格从8.00美元下调至3.00美元。
Genocea Biosciences Trading Down 6.7 %
Genocea Biosciens股价下跌6.7%
Shares of NASDAQ:GNCA opened at $0.01 on Monday. The business's 50-day moving average is $0.03 and its 200 day moving average is $0.56. Genocea Biosciences has a 1 year low of $0.01 and a 1 year high of $2.20. The firm has a market capitalization of $657,820.80, a P/E ratio of -0.02 and a beta of 2.26. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.
纳斯达克：GNCA的股票周一开盘报0.01美元。该业务的50日移动均线切入位在0.03美元，200日移动均线切入位在0.56美元。Genocea Biosciences的一年低点为0.01美元，一年高位为2.20美元。该公司的市值为657,820.80美元，市盈率为-0.02，贝塔系数为2.26。该公司的债务权益比为0.24，流动比率为1.35，速动比率为1.35。
Insider Buying and Selling
内幕买卖
Institutional Trading of Genocea Biosciences
基因生物科学的制度性交易
An institutional investor recently raised its position in Genocea Biosciences stock. Commonwealth Equity Services LLC boosted its holdings in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the quarter. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 59.25% of the company's stock.
一家机构投资者最近提高了对Genocea Biosciences股票的头寸。根据英联邦股票服务公司向美国证券交易委员会的最新披露，该公司在第四季度增持了基因生物科学公司(纳斯达克代码：GNCA-GET评级)的股票49.4%。该机构投资者在本季度额外购买了10,576股后，持有这家生物技术公司31,981股股票。在最近一次报告期结束时，Federal Equity Services LLC拥有Genocea Biosciences约0.06%的股份，价值3.7万美元。机构投资者和对冲基金持有该公司59.25%的股票。
Genocea Biosciences Company Profile
Genocea Biosciences公司简介
(Get Rating)
(获取评级)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences，Inc.是一家生物制药公司，发现和开发新型癌症免疫疗法。该公司使用其专有的发现平台ATLAS，该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Use These To Find Your Stock's Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter's Up For Third Week In A Row: What's Next For The Stock?
- 免费获取StockNews.com关于基因组生物科学的研究报告(GNCA)
- 用这些来找出你的股票的支撑位和阻力位
- 波音股票准备好起飞了吗？
- 埃隆·马斯克出局了，但你应该加入推特股票吗？
- 3个可能令人惊讶的收益公告
- 推特连续第三周上涨：股票的下一步是什么？
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧